Inicio>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>EGFR Inhibitor

EGFR Inhibitor (Synonyms: Epidermal Growth Factor Receptor Inhibitor)

Catalog No.GC11312

El inhibidor de EGFR es una pirimidina disustituida en 4,6 y es un inhibidor de EGFR potente, competitivo con ATP, irreversible y altamente selectivo con una IC50 de 21 nM. El inhibidor de EGFR también inhibe los mutantes EGFRL858R y EGFRL861Q con IC50 de 63 nM y 4 nM, respectivamente. El inhibidor de EGFR muestra una fuerte selectividad por EGFR sobre HER4 (IC50 = 7640 nM) y un panel de otras 55 quinasas. El inhibidor de EGFR induce la apoptosis de las células y tiene actividad antitumoral.

Products are for research use only. Not for human use. We do not sell to patients.

EGFR Inhibitor Chemical Structure

Cas No.: 879127-07-8

Tamaño Precio Disponibilidad Cantidad
1mg
54,00 $
Disponible
5mg
162,00 $
Disponible
25mg
540,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

EGFR inhibitor is a cell permeable, pyrimidine compound that selectively inhibits the EGFR kinase with IC50 value of 21 nM [1].

EGFR is a transmembrane protein, and is a receptor for members of epidermal growth factor family. The binding of EGFR with its ligands induces receptor dimerization and tyrosine autophosphorylation, and leads to cell proliferation. The overactivity of EGFR tyrosine kinases is associated with a number of cancers, inhibition of EGFR can downregulate antiapoptotic proteins such as surviving and upregulate proapoptotic proteins such as Bim. Thus, EGFR inhibitor can induce cell apoptosis, resulting in anti-tumor effectivity [2].

EGFR inhibitor inhibited EGFR kinase in vitro and blocks receptor autophosphorylation in cells. EGFR inhibitor also inhibited L858R and L861Q EGFR mutants with IC50 values of 63 and 4 nM, respectively [1].

References:
1.  Q. Zhang, Y. Liu, F. Gao, et al. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. Journal of the American Chemical Society 128(7), 2182-2183 (2006).
2.  F. Ciardiello, G. Tortora. EGFR antagonists in cancer treatment. New England Journal of Medicine 358(11), 1160-1174 (2008).

Reseñas

Review for EGFR Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for EGFR Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.